- Home
- AZN
AZN
AstraZeneca PLC
as 10-17-2025 3:54pm EST
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
| Founded: | 1992 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 252.9B | IPO Year: | 1993 |
| Target Price: | N/A | AVG Volume (30 days): | 6.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 5.31 | EPS Growth: | 28.86 |
| 52 Week Low/High: | $61.24 - $86.57 | Next Earning Date: | 11-11-2025 |
| Revenue: | $56,501,000,000 | Revenue Growth: | 15.00% |
| Revenue Growth (this year): | 10.82% | Revenue Growth (next year): | 5.99% |
Latest AstraZeneca PLC News
AZN Breaking Stock News: Dive into AZN Ticker-Specific Updates for Smart Investing
Business Wire
9 hours ago
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
Business Wire
13 hours ago
DATROWAY® Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Vs Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02
Simply Wall St.
a day ago
How the Narrative Around AstraZeneca Is Shifting Amid New Risks and Pipeline Developments
Business Wire
a day ago
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial
Investor's Business Daily
a day ago
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
Business Wire
a day ago
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial
Zacks
2 days ago
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
MT Newswires
2 days ago
Amgen, AstraZeneca Say FDA Approves Tezspire for Chronic Rhinosinusitis
Compare AZN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AZN AstraZeneca PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.